ambroxol has been researched along with Premature Rupture of Fetal Membranes in 2 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ambroxol treatment group consisted of 39 subjects in whom 1,000 mg of ambroxol diluted in 500 ml of 5% glucose solution was given intravenously for 4 hours once a day for 3 days, while the control group consisted of 41 subjects in whom ambroxol was not administered." | 2.69 | Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. ( Fernandez, AM; Laoag-Fernandez, JB; Maruo, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sackey, S | 1 |
| Gadzinowski, J | 1 |
| Szymankiewicz, M | 1 |
| Breborowicz, GH | 1 |
| Rudnicki, J | 1 |
| Patalan, J | 1 |
| Rózewicki, K | 1 |
| Laoag-Fernandez, JB | 1 |
| Fernandez, AM | 1 |
| Maruo, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ambroxol and Premature Rupture of Fetal Membranes
| Article | Year |
|---|---|
Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.
Topics: Adult; Ambroxol; Apgar Score; Drug Administration Schedule; Expectorants; Female; Fetal Membranes, P | 2000 |
Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.
Topics: Adult; Ambroxol; Apgar Score; Drug Administration Schedule; Expectorants; Female; Fetal Membranes, P | 2000 |
Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.
Topics: Adult; Ambroxol; Apgar Score; Drug Administration Schedule; Expectorants; Female; Fetal Membranes, P | 2000 |
Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome.
Topics: Adult; Ambroxol; Apgar Score; Drug Administration Schedule; Expectorants; Female; Fetal Membranes, P | 2000 |
1 other study available for ambroxol and Premature Rupture of Fetal Membranes
| Article | Year |
|---|---|
[Comparison of mortality and morbidity in newborns treated with ambroxol prenatally and postnatally].
Topics: Ambroxol; Apgar Score; Female; Fetal Membranes, Premature Rupture; Humans; Incidence; Infant, Newbor | 1995 |